News Headlines Article

FDA advisory panel says Theravance COPD drug should be approved
San Francisco Business Times

An inhaled lung drug developed by Theravance Inc. and GlaxoSmithKline plc moved a step closer to approval Wednesday after getting a positive recommendation from an FDA advisory panel. The treatment, a once-a-day inhaled combination of a corticosteroid (fluticasone furoate) and bronchodilator (vilanterol), abbreviated as FF/VI and branded as Breo Ellipta, got a 9-4 vote in favor of approval from the Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee, or PADAC.